In this review, the trials of the last 10 years related to smoking cessation therapies are reviewed. For this aim medline is searched and especially the randomized, dot ıble-blind, placebo controlled trials are examined in detail. As a result nicotine replacement preparates, bupropion SR and nortriptyline are the pharmacological therapies whose efficacies are proved. Nicotine replacement therapy and bupropion SR reduces withdrawal symptoms as well as weight gain. Bupropion SR also reduces the craving that is the most common reason of relapse. There are some results suggesting that bupropion is effective in preventing relapse especially in women. The results of the first trials of selegiline and lazabemide are giving hope. In the study of lazabemide point prevalance abstinence at the end of 8 week was 17 %, 19 % and 30 % in the placebo, lazabemide 100 mglday and lazabemide 200 mg/day groups, respectively. In the study of selegiline, adding selegiline to nicotine patch was associated with doubling of the 52-week continuous abstinence rate, but this difference was not statistically significant. Selegiline significantly reduced craving for ciga ı ettes. Combined drug therapies may increase the success rates, new trials with different drug combinations can be done.